Mielodysplastic syndromes (MDS) are clonal disorders of the hemopoietic stem cell. About one third of the cases terminate in an acute leukemia, usually acute myeloblastic leukemia. However, few cases of transformation into acute lymphoblastic leukemia (ALL) have been described. We present a case of refractory anemia that transformed into ALL two months after diagnosis and was successfully treated with conventional chemotherapy. Two years later a hyperfibrotic form of MDS was detected in the patient, that soon after terminated in acute megakaryoblastic leukemia. The course of MDS in the present case provides evidence that MDS can involve a pluripotent stem cell, presenting clonal evolution, documented by successive changes in its clinical and hematological features.


INTRODUCTION

The myelodysplastic syndrome (MDS) comprises a heterogeneous group of disorders of the hemopoietic stem cell presenting cytopenias in peripheral blood and cellular bone marrow with cell atypias. About 30% of the MDS develop acute leukemia, usually acute myeloblastic leukemia. However, a small number of cases can transform into acute lymphoblastic leukemia or bilineal or biphenotypic leukemia, suggesting that the origin of this disorder may be at the level of a common progenitor cell that gives rise to hemopoietic as well as lymphoid cells. We describe a case of MDS that presented a transformation into acute lymphoblastic leukemia two months after diagnosis. The patient was treated with polychemotherapy, achieving complete remission and normal bone marrow. Two years later she experienced a recurrence of MDS, that had different features than at initial diagnosis. She developed a new leukemic transformation with characteristics of acute megakaryoblastic leukemia. The course of MDS in this patient favours the hypothesis that the origin of the disorder in this case was at the level of a very early stem cell, developing clonal evolution with pronounced changes in disease pattern and type of leukemic transformation.

CASE REPORT

A 62 year-old white female was seen at the University Hospital, having presented weakness for two months. Moderate pallor and discrete splenomegaly were the only abnormalities found at physical examination. At this time,
the leucocyte count was 2.2 x 10^9/L with 39% neutrophils, 56% lymphocytes, and 5% monocytes. Hemoglobin concentration was 8.4g/dL with an MCV of 97 fl and the platelet count was 330,0 x 10^9/L. Bone marrow aspirate and biopsy were hypercellular with a decrease of the myeloid-erytroid ratio. Blast cell count was 4% of non-erythroid cells. Dysplastic features were present in erithroblastic, granulocytic and megakaryoblastic series. There was a slight increase in reticulin fibres (Fig. 1). These bone marrow findings were consistent with the diagnosis of myelodysplastic syndrome, refractory anemia type, according to the criteria established by the FAB Cooperative Group. Two months later, pallor and splenomegaly got worse. The leucocyte count was 0.8 x 10^9/L with 10% neutrophils, 60% lymphocytes and 30% blast cells. Hemoglobin concentration was 4.5 g/L and the platelet count was 100,0 x 10^9/L. Bone marrow cytology showed an infiltration with small blast cells. Sudan black and chloroacetate esterase stains were negative in those blasts, while a PAS stain showed some granules in a small number of cells (Fig. 2). These findings were consistent with the diagnosis of acute lymphoblastic leukemia. Immunophenotypic analysis of the bone marrow aspirate by flow cytometry showed that leukemic cells were CD19 positive (67%) and SIg, CD2, CD33, and CD34 negative. Induction therapy for ALL with daunomycin, vincristin and prednisone resulted in complete remission. Dysplastic features were not conspicuous in erythroblasts, granulocytes or megakaryocytes, in bone marrow aspirate obtained after induction chemotherapy. The patient was then treated with intensification and maintenance chemotherapy for ALL. Two years later, pallor and splenomegaly returned. The leucocyte count was 2.0 x 10^9/L with 40% neutrophils, 58% lymphocytes, and 2% monocytes. The hemoglobin concentration was 8.2 g/dL,
and platelet count was 95.0 x 10^9/L. The bone marrow biopsy findings showed the reappearance of MDS, now presenting pronounced fibrosis. Some groups of blast cells (ALIP) could be seen on bone marrow histological examination at this time (Fig. 3). Three months later, the patient was readmitted to hospital due to shortness of breath and fever. The leucocyte count was 5.8 x 10^9/L with 34% neutrophils, 12% lymphocytes, and 50% blast cells. The hemoglobin concentration was 7.6 g/dL, and the platelet count was 90.0 x 10^9/L. Bone marrow aspirate findings showed 30% small blast cells with a small rim of cytoplasm, sometimes with blebs (Figure 4). Chloroacetate esterase stain revealed a focal positivity in the blast cells. No positivity was observed in Sudan black and PAS stains. Immunophenotypic analysis of peripheral blood by flow cytometry showed that leukemic cells were CD13 (40%), CD61 (9%) positive and CD2, CD3, CD10, CD19, CD33 negative. Bone marrow histological examination showed a diffuse and homogeneous infiltration with blast cells, many atypical megakaryocytes, and fibrosis (Figure 4). Immunohistochemistry was performed using the avidin-biotin-peroxidase technique (29). Positivity was obtained using the antibody for factor VIII: von Willebrand factor (polyclonal, Dako), whereas UCHL-1 (CD45RO, Dako), L26 (CD20, Dako), and lysozyme (polyclonal, Dako) were negative. The results were consistent with acute megakaryoblastic leukemia. The patient died shortly afterwards from sepsis.

**DISCUSSION**

The present case shows some remarkable features in the course of MDS. At the beginning, peripheral blood...
and bone marrow findings led to the diagnosis of MDS, refractory anemia type, according to FAB criteria. Two months later, overt leukemia developed. The morphologic features of the blasts, their pattern of PAS positivity and their immunological characteristics were those of acute lymphoblastic leukemia (ALL). Conventional chemotherapy for ALL resulted in complete remission that lasted for 25 months. During this period the peripheral blood counts were normal, and no conspicuous atypias could be found in erythroblasts, granulocytes and megakaryocytes. Although the initial findings in this case pointed to the diagnosis of refractory anemia, which usually runs a benign course, the patient developed acute leukemia in a few months. The progression of MDS to ALL is also unusual. Only a few cases showing this evolution have been reported in the literature, and in most of them, refractory anemia with excess of blasts presented a transformation to ALL. In our case, it is possible that ALL may have been the renewed appearance of an etiologically unrelated malignancy, although this form of acute leukemia is far more common in children than in adults in their sixties. However, such an association of events is thought to be very rare. There is much evidence that MDS has its origin in a pluripotent stem cell, producing a variety of abnormalities in the hematopoietic cell lineages and frequently terminating in an acute myeloblastic leukemia. Rarely, MDS may progress to ALL. This has been shown by clonal analysis as well as by the description of alterations in the lymphocytes and the occurrence of autoimmune phenomena in MDS. Therefore, in our case ALL could have been the blast transformation of a refractory anemia. After two years, pancytopenia and a progressive splenomegaly developed. Bone marrow histologic findings disclosed features of MDS, now characterized by severe fibrosis, increase of atypical megakaryocytes and the presence of ALIPs. These features may be interpreted as a new clonal evolution of the disorder. Cases of MDS characterized by trilineage dysplasia, with proliferation of atypical megakaryocytes and bone marrow fibrosis have been repeatedly described as a special form of MDS, frequently found after radio or chemotherapy, that has a high probability of transformation into AML and a poor prognosis. However, it is difficult to exclude the possibility that the chemotherapy regimen, successfully used in the treatment of ALL in this case, was responsible for this clonal evolution. Secondary MDS or acute leukemia have been described in 5% to 10% of patients treated successfully with radiotherapy or polychemotherapy for solid tumors or lymphomas. It is however more common in patients receiving high doses of alkylating agents or etoposide. Our patient received mostly antimetabolites and relatively small doses of antracyclins and cyclophosphamide.

REFERENCES


